| abstract |
The present invention provides molecules that bind to CTLA4 or human serum albumin, such as ISVD and nanobodies. These molecules have been engineered to reduce the occurrence of binding by pre-existing antibodies in the body of the subject to which such molecules are administered. Methods for increasing the immune response using the molecule, for treating cancer and / or for treating infectious diseases are provided. |